Winner Medical(SZ:300888) Sou Hu Cai Jing·2026-02-11 13:13Core Viewpoint - The financial performance of Steady Medical (300888) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating a strong operational performance in the medical and personal care sectors [2]. Financial Performance - For the first three quarters of 2025, Steady Medical reported a main revenue of 7.897 billion yuan, an increase of 30.1% year-on-year [2]. - The net profit attributable to shareholders reached 732 million yuan, up 32.36% year-on-year [2]. - The net profit after deducting non-recurring items was 679 million yuan, reflecting a 43.93% increase year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 2.601 billion yuan, a year-on-year increase of 27.71% [2]. - The net profit for Q3 2025 was 240 million yuan, up 42.11% year-on-year [2]. - The net profit after deducting non-recurring items for Q3 was 218 million yuan, marking a 50.77% increase year-on-year [2]. - The company's debt ratio stands at 33.87%, with investment income of 33.23 million yuan and financial expenses of -2.036 million yuan [2]. - The gross profit margin is reported at 48.32% [2]. Market Activity - As of February 11, 2026, Steady Medical's stock closed at 35.39 yuan, with a slight decrease of 0.03% [1]. - The trading volume was 19,200 hands, with a total transaction amount of 68.0836 million yuan [1]. - The net outflow of main funds was 13.0146 million yuan, accounting for 19.12% of the total transaction amount [1]. - Retail investors showed a net inflow of 13.4785 million yuan, representing 19.8% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 8 institutions have provided ratings for Steady Medical, with 7 buy ratings and 1 hold rating [2]. - The average target price set by institutions over the past 90 days is 5.451 billion yuan [2].